Trial Profile
Activity and Safety of Third Line Tyrosin Kinase Inhibitor (TKI) After 2 Tyrosin Kinase Inhibitors (TKIs) in Patients With Metastatic Renal Cell Carcinoma (mRCC) (Tokio Study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TOKIO; Tokio Study
- 09 Mar 2018 New trial record